Mercaptopurine Holsten

Mercaptopurine, the active ingredient in Mercaptopurine Holsten, is an antimetabolite presented as an oral formulation for oral use. It is employed in the treatment of certain leukemias and inflammatory bowel disease, targeting rapidly dividing cells. It is indicated for acute lymphoblastic leukemia, chronic myeloid leukemia, and inflammatory bowel disease, and is administered under physician supervision.

GNH USA supplies Mercaptopurine Holsten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring quality assurance and regulatory compliance throughout the supply chain.

Mercaptopurine is used in antineoplastic therapy targeting malignant hematologic cells and in immune‑mediated gastrointestinal disorders. - Acute lymphoblastic leukemia: helps achieve remission by inhibiting proliferation of leukemic lymphoblasts. - Chronic myeloid leukemia: contributes to disease control by suppressing abnormal myeloid cell growth. - Inflammatory bowel disease: reduces intestinal inflammation by modulating immune cell activity.

Mercaptopurine may cause a range of adverse reactions, varying from mild, transient symptoms to potentially life‑threatening conditions that require immediate medical attention.

Common Side Effects: - Nausea: mild to moderate stomach upset that may affect appetite. - Vomiting: occasional episodes, often accompanying nausea. - Loss of appetite: reduced desire to eat, potentially leading to weight loss. - Fatigue: persistent tiredness that can interfere with daily activities.

Serious or Rare Side Effects: - Bone marrow suppression: decreased production of blood cells causing anemia, leukopenia or thrombocytopenia. - Severe infections: heightened risk due to immune system weakening, requiring prompt medical attention. - Hepatotoxicity: liver enzyme elevations or hepatitis that may indicate liver injury. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain and digestive disturbances. These events are uncommon but require close clinical monitoring.

When prescribing mercaptopurine, clinicians should observe several precautionary measures to ensure patient safety. - Monitor blood counts: regular complete blood count testing to detect bone marrow suppression. - Assess liver function: periodic liver enzyme tests to identify hepatotoxicity. - Evaluate renal function: adjust dosing in patients with impaired kidney clearance. - Avoid use in known hypersensitivity: discontinue if allergic reactions such as rash or fever occur. - Adjust dose in hepatic impairment: reduce dose according to liver function test results. - Store at room temperature: keep in the original container, protect from moisture and light.

Mercaptopurine can interact with several medicines, affecting its efficacy or toxicity.

Major Interactions (Avoid): - Allopurinol: may increase mercaptopurine toxicity leading to severe bone marrow suppression. - Thiopurine methyltransferase (TPMT) deficiency: genetic lack of activity heightens risk of adverse effects; avoid or adjust dose. - Azathioprine: cross‑reactivity can cause additive myelosuppression.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Methotrexate: combined use can increase hematologic toxicity and liver injury.